U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

DS Stage III Plasma Cell Myeloma

MedGen UID:
82969
•Concept ID:
C0278724
•
Neoplastic Process
Synonyms: DS Stage III Multiple Myeloma; Durie/Salmon Stage III Multiple Myeloma; Durie/Salmon Stage III Plasma Cell Myeloma; Multiple Myeloma Stage III; Stage III Multiple Myeloma; Stage III Plasma Cell Myeloma

Definition

Plasma cell myeloma with one or more of the following: 1. Hemoglobin less than 8.5 g/dL. 2. Serum calcium greater than 12.0 mg/dL. 3. More than three lytic bone lesions. 4. High M protein production as shown by: a. IgG greater than 7.0 g/dL. b. IgA greater than 5.0 g/dL. c. Urinary kappa or lamda greater than 12.0 g/24 hours. Estimated myeloma cell mass: greater than 1.2 trillion (1012)/m2 (high burden). The following subclassification of stages is used: a. Creatinine less than 2.0 mg/dL. b. Creatinine greater than or equal to 2.0 mg/dL. Serum beta-2-microglobulin has been shown to be a reliable marker for prognosis. Since the great majority of symptomatic myeloma patients are classified as stage III by the Durie/Salmon criteria, this staging system has not proven to be very useful for identifying the patients with intermediate and poor prognosis. Note that the newer International Staging System defines stage III quite differently: Beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months). (PDQ) [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVDS Stage III Plasma Cell Myeloma

Professional guidelines

PubMed

Diagnosis and treatment of multiple myeloma in Hunan Province.
Liu F, Cheng Q, Song K, Yu H, Li J, Zhang H, Hu G, Zhou M, Wang J, Ding Z, Luo Z, Peng T, Ding L, Zhao L, Liu J, He Y, Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban 2022 Apr 28;47(4):497-504. doi: 10.11817/j.issn.1672-7347.2022.210555. PMID: 35545345Free PMC Article

Recent clinical studies

Etiology

Diagnosis and treatment of multiple myeloma in Hunan Province.
Liu F, Cheng Q, Song K, Yu H, Li J, Zhang H, Hu G, Zhou M, Wang J, Ding Z, Luo Z, Peng T, Ding L, Zhao L, Liu J, He Y, Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban 2022 Apr 28;47(4):497-504. doi: 10.11817/j.issn.1672-7347.2022.210555. PMID: 35545345Free PMC Article
Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma.
Szudy-Szczyrek A, Mlak R, Mielnik M, Mazurek M, Chocholska S, Podgajna M, Szczyrek M, Homa-Mlak I, Małecka-Massalska T, Hus M
Cells 2022 Feb 21;11(4) doi: 10.3390/cells11040752. PMID: 35203396Free PMC Article
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M
Lancet Oncol 2022 Jan;23(1):65-76. Epub 2021 Dec 3 doi: 10.1016/S1470-2045(21)00579-9. PMID: 34871550
Characterizing the Tumor Suppressor Role of CEACAM1 in Multiple Myeloma.
Xu J, Liu B, Ma S, Zhang J, Ji Y, Xu L, Zhu M, Chen S, Wu X, Wu D
Cell Physiol Biochem 2018;45(4):1631-1640. Epub 2018 Feb 21 doi: 10.1159/000487730. PMID: 29486474
Multiple myeloma in elderly patients: presenting features and outcome.
Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P
Eur J Haematol 2001 Jan;66(1):11-7. doi: 10.1034/j.1600-0609.2001.00301.x. PMID: 11168502

Diagnosis

Diagnosis and treatment of multiple myeloma in Hunan Province.
Liu F, Cheng Q, Song K, Yu H, Li J, Zhang H, Hu G, Zhou M, Wang J, Ding Z, Luo Z, Peng T, Ding L, Zhao L, Liu J, He Y, Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban 2022 Apr 28;47(4):497-504. doi: 10.11817/j.issn.1672-7347.2022.210555. PMID: 35545345Free PMC Article
Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma.
Szudy-Szczyrek A, Mlak R, Mielnik M, Mazurek M, Chocholska S, Podgajna M, Szczyrek M, Homa-Mlak I, Małecka-Massalska T, Hus M
Cells 2022 Feb 21;11(4) doi: 10.3390/cells11040752. PMID: 35203396Free PMC Article
Characterizing the Tumor Suppressor Role of CEACAM1 in Multiple Myeloma.
Xu J, Liu B, Ma S, Zhang J, Ji Y, Xu L, Zhu M, Chen S, Wu X, Wu D
Cell Physiol Biochem 2018;45(4):1631-1640. Epub 2018 Feb 21 doi: 10.1159/000487730. PMID: 29486474
Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.
Chinen Y, Kuroda J, Shimura Y, Nagoshi H, Kiyota M, Yamamoto-Sugitani M, Mizutani S, Sakamoto N, Ri M, Kawata E, Kobayashi T, Matsumoto Y, Horiike S, Iida S, Taniwaki M
Cancer Res 2014 Dec 15;74(24):7418-29. Epub 2014 Sep 30 doi: 10.1158/0008-5472.CAN-14-1420. PMID: 25269480
Multiple myeloma in elderly patients: presenting features and outcome.
Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P
Eur J Haematol 2001 Jan;66(1):11-7. doi: 10.1034/j.1600-0609.2001.00301.x. PMID: 11168502

Therapy

Diagnosis and treatment of multiple myeloma in Hunan Province.
Liu F, Cheng Q, Song K, Yu H, Li J, Zhang H, Hu G, Zhou M, Wang J, Ding Z, Luo Z, Peng T, Ding L, Zhao L, Liu J, He Y, Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban 2022 Apr 28;47(4):497-504. doi: 10.11817/j.issn.1672-7347.2022.210555. PMID: 35545345Free PMC Article
Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma.
Szudy-Szczyrek A, Mlak R, Mielnik M, Mazurek M, Chocholska S, Podgajna M, Szczyrek M, Homa-Mlak I, Małecka-Massalska T, Hus M
Cells 2022 Feb 21;11(4) doi: 10.3390/cells11040752. PMID: 35203396Free PMC Article
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M
Lancet Oncol 2022 Jan;23(1):65-76. Epub 2021 Dec 3 doi: 10.1016/S1470-2045(21)00579-9. PMID: 34871550
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, Bellò M, Gallamini A, Patriarca F, Gay F, Gamberi B, Ghedini P, Cavo M, Fanti S, Zamagni E
Eur J Nucl Med Mol Imaging 2018 May;45(5):712-719. Epub 2017 Dec 21 doi: 10.1007/s00259-017-3909-8. PMID: 29270787
Multiple myeloma in elderly patients: presenting features and outcome.
Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P
Eur J Haematol 2001 Jan;66(1):11-7. doi: 10.1034/j.1600-0609.2001.00301.x. PMID: 11168502

Prognosis

Diagnosis and treatment of multiple myeloma in Hunan Province.
Liu F, Cheng Q, Song K, Yu H, Li J, Zhang H, Hu G, Zhou M, Wang J, Ding Z, Luo Z, Peng T, Ding L, Zhao L, Liu J, He Y, Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban 2022 Apr 28;47(4):497-504. doi: 10.11817/j.issn.1672-7347.2022.210555. PMID: 35545345Free PMC Article
Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma.
Szudy-Szczyrek A, Mlak R, Mielnik M, Mazurek M, Chocholska S, Podgajna M, Szczyrek M, Homa-Mlak I, Małecka-Massalska T, Hus M
Cells 2022 Feb 21;11(4) doi: 10.3390/cells11040752. PMID: 35203396Free PMC Article
The status of jaw lesions and medication-related osteonecrosis of jaw in patients with multiple myeloma.
Lu SY, Ma MC, Wang MC, Hsue SS
J Formos Med Assoc 2021 Nov;120(11):1967-1976. Epub 2021 Feb 4 doi: 10.1016/j.jfma.2021.01.015. PMID: 33551311
Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases.
Qian J, Jin J, Luo H, Jin C, Wang L, Qian W, Meng H
Hematology 2017 Sep;22(8):472-476. Epub 2017 May 2 doi: 10.1080/10245332.2017.1309493. PMID: 28463078
Multiple myeloma in elderly patients: presenting features and outcome.
Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P
Eur J Haematol 2001 Jan;66(1):11-7. doi: 10.1034/j.1600-0609.2001.00301.x. PMID: 11168502

Clinical prediction guides

Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma.
Szudy-Szczyrek A, Mlak R, Mielnik M, Mazurek M, Chocholska S, Podgajna M, Szczyrek M, Homa-Mlak I, Małecka-Massalska T, Hus M
Cells 2022 Feb 21;11(4) doi: 10.3390/cells11040752. PMID: 35203396Free PMC Article
The status of jaw lesions and medication-related osteonecrosis of jaw in patients with multiple myeloma.
Lu SY, Ma MC, Wang MC, Hsue SS
J Formos Med Assoc 2021 Nov;120(11):1967-1976. Epub 2021 Feb 4 doi: 10.1016/j.jfma.2021.01.015. PMID: 33551311
The Role of (18)F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie-Salmon Plus and Other Staging Systems.
Deng S, Zhang B, Zhou Y, Xu X, Li J, Sang S, Zhang W
Contrast Media Mol Imaging 2018;2018:4198673. Epub 2018 Jul 30 doi: 10.1155/2018/4198673. PMID: 30154686Free PMC Article
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, Bellò M, Gallamini A, Patriarca F, Gay F, Gamberi B, Ghedini P, Cavo M, Fanti S, Zamagni E
Eur J Nucl Med Mol Imaging 2018 May;45(5):712-719. Epub 2017 Dec 21 doi: 10.1007/s00259-017-3909-8. PMID: 29270787
Multiple myeloma in elderly patients: presenting features and outcome.
Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P
Eur J Haematol 2001 Jan;66(1):11-7. doi: 10.1034/j.1600-0609.2001.00301.x. PMID: 11168502

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...